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We measured cerebrospinal ﬂuid (CSF) levels of the soluble isoforms of amyloid precursor protein (APP; sAPPα sAPPβ) and other
CSF biomarkers in 107 patients with Alzheimer’s disease (AD), dementia with Lewy body dementia (DLB), Parkinson’s disease
dementia (PDD), and normal controls (NC) using commercial kits. DLB and PDD were combined in a Lewy body dementia
g r o u p( L B D ) .N od i ﬀerences were observed in sAPPα and sAPPβ levels between the groups. Signiﬁcant correlations were observed
between sAPPα and sAPPβ and between sAPPβ and Mini-Mental State Examination scores in the total group analysis as well as
when LBD and AD groups were analyzed separately. sAPPα and sAPPβ levels correlated with Aβ38, Aβ40, Aβ42, and Tau in the
LBD group. In AD, sAPPα correlated with p-Tau and sAPPβ with Aβ40. The diﬀerential association between sAPPα and sAPPβ
withAβ and Tau species between LBD and AD groups suggests a possible relationship with the underlying pathologies in LBD and
AD.
1.Introduction
Cerebrospinal ﬂuid (CSF) levels of amyloid beta peptides
(Aβ) and Tau proteins have shown good accuracy in
distinguishing early Alzheimer’s disease (AD) from healthy
elderly controls [1], but studies from dementia with Lewy
bodies (DLB) and Parkinson’s disease dementia (PDD) are
scarce.
The Aβ peptides originate from the transmembranous
amyloid precursor protein (APP) after sequential cleavage
by proteases known as β-a n dγ-secretases [2]. Even though
APP is ubiquitously expressed, its physiological role is
not yet known [3]. Some studies suggest a role of APP
in neuronal survival and migration, neurite outgrowth,
synaptic plasticity, and cell adhesion [4]. Cleavage of APP
by α-secretase generates a soluble protein known as sAppα,
which precludes the formation of the toxic 42 amino acid
long Aβ peptide (Aβ42) [3, 4].
The toxic Aβ42 peptide as well as the shorter nontoxic
and more abundant Aβ variants (Aβ38 and Aβ40) are
generated following the amyloidogenic pathway which starts
by extra cellular cleavage of APP by the enzymes BACE
and γ-secretase and results in the production of soluble
sAPPβ. Thus sAPPα and sAPPβ are secreted APP fragments.
However, the physiological role of these peptides is not well
established. Production of sAPPα increases in response to
electrical activity and activation of muscarinic acetylcholine
receptors [5] as well as increasing synaptic and neurotrophic
activities [6]. Until recently the physiological role of sAPPβ
was associated mainly with the amyloidogenic pathway in
AD. However, a recent investigation by Li et al. presented a
new possible role for the soluble sAPPβ as a transcriptional2 International Journal of Alzheimer’s Disease
enhancer for some proteins that seem to be involved in the
APP cascade [7].
Inconsistent results have been reported among the few
studies exploring CSF levels of sAPPα and sAPPβ as poten-
tial biomarkers for AD. Lewczuk and coworkers recently
reported signiﬁcant increases of both sAPPα and sAPPβ in
neurochemically veriﬁed AD patients in comparison to a
group consisting of nonneurochemically veriﬁed dementia
cases [8], and Gabelle et al. reported similar ﬁndings [9]. In
contrast, Zetterberg et al. detected no signiﬁcant diﬀerences
between AD patients and cognitively healthy controls [10],
and an earlier study by Olsson et al. [11] found no
signiﬁcant diﬀerences in sAPPα or sAPPβ levels between
healthycontrolsandpatientswithsporadicAD.However,the
level of sAPPβ was elevated in patients with mild cognitive
impairment compared to controls [11].
Neuropathological[12]andCSF[13]studieshaveshown
that pathological processing of amyloid occurs also in
DLB and PDD, which represent 15–20% of the dementia
population [14]. Thus, it is possible that these proteins may
somehow be involved in the pathogenesis of these diseases
as well as in AD. To our knowledge, the levels of sAPPα and
sAPPβ have not yet been investigated in patients with DLB
and PDD [15]. In this study our objective was to examine
the CSF level of sAPPα and sAPPβ in patients with AD,
D L B ,P D D ,a n dn o r m a lc o n t r o l s( N C ) .As e c o n do b j e c t i v e
was to explore clinical and neurochemical correlates of
CSF sAPPα and sAPPβ levels, to assess their relationship
with disease severity as a measure of underlying brain
pathology.
2. Methods
2.1. Subjects. Patients were drawn from two cohorts in
Scandinavia: the DemWest study recruited patients with
mild dementia from all geriatric, psychiatric and neurology
outpatient clinics in Rogaland and Hordaland counties in
Western Norway between 2005–2007 [14]. Out of the total
225 patients, 55 individuals consented for lumbar puncture
and CSF collection, and those with AD (n = 31), DLB (n =
9),or PDD (n = 3) were included in the study. Twelveelderly
subjectswithoutasubjectivecognitiveimpairmentorknown
brain disease and MMSE score of >25 who consented to
lumbar puncture at the StavangerUniversity Hospital during
orthopaedic surgery or neurologic outpatient assessment
wereincludedasnondementedcontrols(NC).Acohortfrom
the Neuropsychiatric Clinic, Sk˚ ane University Hospital in
southern Sweden consisted of patients with PDD (n = 18)
and probable DLB (n = 15) who participated in a clinical
trial of memantine [16], and of 19 patients with AD from the
Outpatient Memory Clinic.
Diagnostic procedures are described in detail elsewhere
[14, 16, 17]. In brief, all patients were diagnosed according
toclinicalconsensuscriteriaforprobableDLB[18],probable
AD [19] or PDD [20] after a detailed clinical assessment by
a registered specialist in psychiatry, neurology, or geriatric
medicine,usingstandardisedandvalidatedquestionnairefor
functional consequences of cognitive impairment [21]a n d
neuropsychological testing.
2.2. Preanalytical Treatment of CSF. Lumbar puncture (LP)
was performed in the L3-L4 or L4-L5 interspace, and CSF
sampling was performed in all cases between 7–10 am in
order to minimize diurnal variation of the level of CSF Aβ
[22]. The ﬁrst 3–4mLs of the CSF were dedicated for routine
analyses for assessment of relevant CSF abnormalities, and
immediately sent on ice to the routine laboratory where
c e l lc o u n t sa n dm e a s u r e m e n t so fg l u c o s ea n dp r o t e i n
were performed. Study samples were collected in separate
polypropylene tubes, and centrifuged at 2000×g, 4◦Cf o r
10min to get rid of cell debris and other insoluble mate-
rials. Following centrifugation, samples were aliquoted and
immediately frozen at −80◦C until analyses were performed.
Samples from the DemWest study, Stavanger, were originally
stored in larger volumes, thus the portions of samples used
in this study were aliquots derived from samples frozen and
thawed (on ice) once.
2.3. sAPPα and sAPPβ Assay in Patients CSF by Electro-
chemiluminescence Assay. All CSF analyses were performed
randomized and in duplicate the same day by E. Mulugeta,
blinded to clinical information. CSF levels of sAPPα and
sAPPβ were determined using the multiplex assay (Human
Aβ peptide Ultra-Sensitive Kits) developed by Meso Scale
Discovery, Gaithersburg, Maryland, USA. The assay uses
the 6E10 antibody to capture sAPPα and a neoepitope-
speciﬁc antibody to capture sAPPβ, combined with the
sulfotagged antibody P2-1 (reacting with the N-terminal
domain of APP) for detection. The assay technology is
based on MULTI-ARRAY technology combining electro-
chemiluminescence detection and patterned arrays oﬀering
combination of sensitivity and dynamic range. The assay
was performed on CSF samples from patients and control
subjectswerediluted1:4andstandardsofsAPPαandsAPPβ
(in concentration range 7.8–500ng/mL) were prepared and
ﬁnally all samples and standards were run in duplicate, and
assay procedures were applied as recommended in the man-
ufacturer’s instructions. Finally electrochemiluminescence
signals were captured from photo detectors, and signals were
processedusingthesoftwareDiscoveryWorkbench3(MSD).
Standard concentrations of each analyte were plotted in a 4-
parameter logistic ﬁt curve and the concentration values of
the unknown samples were computed.
2.4. Analyses of Aβ Peptides and Tau Protein. The analytical
methods for triplex Aβ38, Aβ40, Aβ42, as well as Tau and P-
Tau assays have been described previously [13]. P-Tau levels
were available only for 31 of the 50 AD cases.
2.5. Statistics and Analytical Procedures. In the ﬁnal analyses
a total of 107 subjects were included: 50 AD, 45 LBD, and
12 NC. Demographics of the patients and control subjects
are shown in Table 1. The groups did not diﬀer by age. DLB
and PDD groups displayed signiﬁcant diﬀerence in disease
duration, as expected due to the relatively long duration
with pure motor symptoms in PD before dementia, but not
on other demographic data, clinical, or biochemical values
(Tables 1 and 2). They were therefore combined in a Lewy-
body disease group (LBD) for the subsequent analyses. MeanInternational Journal of Alzheimer’s Disease 3
Table 1: Demographic and clinical characteristics of the diagnostic groups.
Diagnosis groups NC (n = 12) AD (n = 50) DLB (n = 24) PDD (n = 21) P
Gender (F/M) 7/5 30/20 7/17 7/14 0.034
Age, y 74.1 (8.3) 74.4 (8.1) 74.0 (7.1) 73.6 (7.0) —
MMSE 28.6 (0.9) 21.1 (4.9) 21.8 (4.0) 20.4 (4.9) 0.000(1)
Disease duration, y Na 2.2 (1.3) 4.1 (3.1) 7.0 (4) 0.0002(2)
Education, y 10.2 (3.0) 10.1 (.3.) (n = 27) 9.3 (2.4) 9.3 (2.8) 0.8
NC: normal controls, AD: Alzheimer’s disease, DLB: dementia with Lewy bodies, PDD: Parkinson’s disease dementia; Na: not applicable.
Numbers represent mean (standard deviation) or number of patients.
(1)Signiﬁcant diﬀerence between NC and the disease groups. No signiﬁcant diﬀerence between disease groups.
(2)Signiﬁcant diﬀerence between PDD and the two other disease groups. No signiﬁcant diﬀerence between DLB and AD.
Table 2: Comparison of CSF values between groups.
NC (n = 12) AD (n = 50) DLB (n = 24) PDD (n = 21) P∗
Aβ38 [pg/mL] (SD) 785 (399) 814 (468) 384 (277) 366 (209) 0.000
Aβ40 [pg/mL] (SD) 7835 (3152) 5297 (1813) 5833 (3033) 262 (206) 0.006
Aβ42 [pg/mL] (SD) 479 (282) 275 (121) 262 (206) 264 (115) 0.001
Tau [pg/mL] (SD) 269 (119) 600 (291) 297 (109) 308 (201) 0.000
P-Tau [pg/mL] (SD) 58 (24) n = 7 89 (38) n = 39 63 (26) n = 20 66 (28) n = 19 0.008
sAppα [ng/mL] (SD) 744 (259) 716 (209) 646 (212) 728 (271) 0.677
sAppβ [ng/mL] (SD) 413 (84) 380 (86) 364 (88) 387 (99) 0.585
∗Kruskal-Wallis test.
MMSE score between the AD group and the LBD group did
notdiﬀersigniﬁcantly.ValuesofCSFmarkerswereexpressed
as absolute (ng/mL) for sAPPα and sAPPβ and (pg/mL) for
Aβ38, Aβ40, Aβ42, and Tau. Between-group comparisons
were performed by using chi-square tests or Kruskall-Wallis
followed by Mann Whitney U test. Correlations between
levels of CSF analytes and demographic and clinical features
were performed using Spearman correlation for nonpara-
metric analyses. Correlations were considered signiﬁcant if
they reached the 0.05 level (2-tailed) and highly signiﬁcant at
the 0.01 level (2-tailed).
3. Results
The standard ranges for sAPPα and sAPPβ were 7.81–
500ng/mL. The lower limit of detection for sAPPα was
(3.88ng/mL) and plate-to-plate variation on lower range
of detection was 14%. For sAPPβ the lower range of
detection was (2.25ng/mL) and plate to plate variation on
the lower range of detection was 12%. To determine inter-
and intraassay variations we have chosen to analyze one
CSF sample on each occasion/plate as a run control. The
interassay variability (same sample analyzed on diﬀerent
plates n = 6) for sAPPα and sAPPβ was 13% and 12%,
respectively. The analytical performance of the Aβ and Tau
measurements have been described previously [13].
3.1. Levels of sAPPα and sAPPβ. For the total group, mean
(SD) of sAPPα was 706 (228)ng/mL, and sAPPβ was 382
(89). There were no signiﬁcant diﬀerences observed in the
levels of sAPPα (P = 0.68) and sAPPβ (P = 0.59) between
the groups (Table 2).
3.2. Correlations. The correlations between sAPPα and
sAPPβ l e v e l sa n dM M S Es c o r e sa sw e l la sl e v e l so fA β
peptides and Tau are shown in Table 3. Highly signiﬁcant
correlations were found between sAPPα and sAPPβ in all
groups (Table 3). MMSE correlated signiﬁcantly with both
sAPPα and sAPPβ in the total group, but was signiﬁcantly
associatedonlywithsAPPβinLBDandADgroups.However,
the correlation factors of sAPPα in the patient groups were
rather similar to the control group, suggesting that the lack
of signiﬁcance is related to the smaller sample size in the
individual groups. In the LBD group signiﬁcant correlations
were found between sAPPα and sAPPβ with all Aβ species
and T-Tau, but not P-tau. In the AD group a signiﬁcant
association was observed only between sAPPβ and Aβ40 and
between sAPPα and P-tau.
4. Discussion
This study examines the CSF levels of sAPPα and sAPPβ
in patients with LBD and AD. We found no diﬀerence
between AD and LBD patients and normal controls using
multiplex immunoassay method. Another ﬁnding was the
highly signiﬁcant correlations between sAPPα and sAPPβ
in all groups. A key ﬁnding was that MMSE scores were
associated with sAPPβ, but less so with sAPPα,i nA Da n d
LBD groups. Finally, there were associations between both
sAPPs and all Aβ species and T-Tau in the LBD group4 International Journal of Alzheimer’s Disease
Table 3: Correlations between CSF analytes and MMSE score.
MMSE Aβ38 Aβ40 Aβ42 Tau P-Tau† sAppβ
All diagnoses together
(total group n = 107)
sAppα 0.206∗ 0.337∗∗ 0.291∗∗ 0.220∗ 0.285∗∗ 0.411∗∗ 0.876∗∗
sAppβ 0.384∗∗ 0.295∗∗ 0.549∗∗ 0.233∗ 0.074 0.329∗∗ —
Tau −0.241∗ 0.718∗∗ 0.001 0.193 — — 0.113
P-Tau 0.133 0.488∗∗ 0.259∗ −0.103 — — 0.329∗∗
NC (n = 12)
sAppα −0.059 0.622∗ 0.497 0.643∗ 0.286
0.357
Obs
n = 7
0.865∗∗
sAppβ 0.018 0.658∗ 0.616∗ 0.515 0.214 0.429
n = 7
—
Tau 0.386 0.464 0.393 0.429 — — 0.214
P-Tau −0.540 0.964∗∗ 0.821∗ 0.857∗∗ — — 0.429
AD (n = 50)
sAppα 0.179 0.071 0.009 −0.093 0.146 0.570∗∗
n = 31
0.811∗∗
sAppβ 0.422∗∗ −0.123 0.395∗∗ −0.168 −0.154 0.340
n = 31
—
Tau −0.579∗∗ 0.723∗∗ −0.371∗∗ 0.330∗ NR NR −0.154
P-Tau 0.107 0.454∗ 0.148 −0.132 — — 0.340
LBD (n = 45)
sAppα 0.289 0.537∗∗ 0.430∗∗ 0.417∗∗ 0.428∗∗ 0.252 0.927∗∗
sAppβ 0.371∗ 0.663∗∗ 0.608∗∗ 0.498∗∗ 0.446∗∗ 0.274 —
Tau 0.234 0.675∗∗ 0.629∗∗ 0.362∗ — — 0.446∗
P-Tau 0.255 0.510∗∗ 0.431∗∗ 0.134 — — 0.274
DLB (n = 24)
sAppα 0.297 0.481∗ 0.461∗ 0.359
P = 0.09
0.377 0.408 0.930∗∗
sAppβ 0.314 0.527∗∗ 0.600∗∗ 0.401
P = 0.058
0.274 0.299 —
Tau 0.156 0.581∗∗ 0.471∗ 0.185 — — 0.274
P-Tau 0.422 0.421 0.211 −0.060 — — 0.299
PDD (n = 21)
sAppα 0.300 0.593∗∗ 0.456∗ 0.542∗ 0.483∗ 0.185 0.902∗∗
sAppβ — 0.791∗∗ 0.641∗∗ 0.644∗∗ 0.618∗∗ 0.312 —
Tau 0.249 0.809∗∗ 0.850∗∗ 0.565∗∗ NR NR 0.618∗∗
P-Tau 0.110 0.624∗∗ 0.792∗∗ 0.315 NR NR 0.312
Spearmancorrelation.Numbersrepresentρ values. ∗Correlationissigniﬁcantatthe0.05level, ∗∗correlationissigniﬁcantatthe0.01level.NR =norelevance.
†P-Tau: incomplete data (total n = 78).
whereas in the AD group there were association between
sAPPβ and Aβ40 and between sAPPα and P-tau.
Following the assumption of alternative APP processing
in either the amyloidogenic or nonamyloidogenic way, one
would expect a reverse correlation of sAppα to sAPPβ.
However, we found a positive correlation, which is consistent
with previous studies [8–10]. The reason why the CSF
levels of these APP isoforms correlate tightly is unknown,
but may suggest that the expression of APP isoforms are
regulated by similar stimuli and pathways, and thus that
they have similar functions. Alternatively, only the secretion
of the APP isoforms into the extracellular space and CSF
are coregulated. Another possible explanation could be the
presence of another factor that regulates the activity of the
enzymes involved in the APP processing.
5.Association of sAPPs with Dementia Severity
andOther CSFMarkers
The association between MMSE and sAPP might suggest
that secretion of sAPPβ into the CSF is associated withInternational Journal of Alzheimer’s Disease 5
less severe pathology as a result of less Aβ42 deposition
and plaque formation and might represent less severity and
perhaps a potential protective mechanism. The potentially
neuroprotective properties of sAPPβ discussed by Li et al.
[7] may overbalance the neurotoxic potential of Aβ42. In cell
studies it has been suggested that APP fragments regulate
behavioral learning and memory [23–27]. The association
between MMSE score and the sAPPβ both in AD and DLB
patients are to some extent consistent with ﬁndings in cell
modelssuggestingthatcognitive functioninADorLBDmay
be are aﬀected by altered levels and activity of the diﬀerent
APP fragments.
Whereas our ﬁndings of no diﬀerence between the
diagnosticgroupsareinlinewithsomepreviousstudies,they
contrast with some others studies [8, 9]. Although similar
methods for measuring sAPP were used, possible explana-
tions for inconsistent ﬁnding are that in the two previous
studies, the non-AD group included mainly patients with
frontotemporal dementia.
We speculate that sAPPβ release somehow stimulates
brain plasticity, which might correlate with higher MMSE in
alldiseasegroupsandTaulevelsintheuppernormalrangein
LBD(CSFTaulevelsinthenormalrangemightbeaplasticity
marker) [28]. However, it should be emphasized that these
data are in need of replication in other studies and larger
cohorts.
The diﬀerential association between sAPPα and sAPPβ
with the classical AD markers amyloid and Tau pathology
in AD compared to LBD suggests diﬀerent pathological
mechanisms. This might be related to the more severe
amyloid and tau pathologies in AD compared to DLB and
PD, or it is possible that α-synuclein pathology in some way
aﬀects the association between sAPPα and sAPPβ with the
development of AD pathology.
In AD, the Aβ species most likely reﬂect the primary and
fundamental pathologic events. Speciﬁcally, amyloid deposi-
tion is correlated to low CSF levels of Aβ42 and its ratio to
Aβ40/Aβ38. T-Tau is a marker of axonal neurodegeneration
whereas P-Tau is a marker of Tau hyperphosphorylation
and neuroﬁbrillary tangle formation [1]. Thus, the observed
correlation of both sAPPs with T-Tau, especially in the
LBD group, suggests that the sAPPs are involved in axonal
processing that in turn may indicate ongoing axonal damage.
6.Methodological Limitations
Methodological limitations which might inﬂuence the ﬁnd-
ings include the relatively small number of patients with low
statistical power. Also, this was an exploratory study, and we
did not adjust for the large number of comparisons when
correlation analyses were performed. Our ﬁndings should
therefore be interpreted with caution.
The controls were not assessed with standard neu-
ropsychological tests. Although they were without subjec-
tive cognitive complaints, a subtle cognitive impairment
indicating very early AD cannot be completely excluded.
Finally, patients were recruited from two diﬀerent centres.
However, the diagnostic procedures at the two centres were
harmonized through several meetings and the use of the
same protocols, but no formal reliability analyses were
performedtoassesstheconsistencyasthenumberofpatients
in individual patient group was not so large.
7. Conclusions
Although the CSF levels of sAPPα and sAPPβ did not
diﬀer between AD, DLB, and NC, there were disease-speciﬁc
diﬀerences in their associations with Aβ and Tau species.
Furtherstudiesareneededtoexplorethis,andtoexplorehow
these peptides are associated with dementia severity.
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